Fulgent Reports Third Quarter 2026 Financial Results
Business Wire•05/11/2026•16:05 ET
0
Key Highlights
- ➤Revenue $90.4 million, growing approximately 8% year-over-year
- ➤GAAP loss $13.2 million, or $(0.48) per share
- ➤2026 revenue guidance maintained at $330.0-$340.0 million
- ➤2026 Non-GAAP loss outlook improves to approximately $46.0-$50.0 million
- ➤4.1 million shares repurchased year-to-date, using $64.1 million cash
Expert Statements
Ming Hsieh, Chairman of the Board of Directors and Chief Executive Officer of Fulgent Genetics, Inc.
“We are encouraged by the momentum in our therapeutics pipeline, with both FID-007 and FID-022 using our nano-drug delivery platform. In our laboratory services business, we continue to integrate AI into our workflow as utilization scales and reliability substantially increases. We expect to continue to expand our AI portfolio to drive further improvements to efficiency and quality.”
Paul Kim, Chief Financial Officer of Fulgent Genetics, Inc.
“We are pleased with our third quarter results, driven by the improvement in our collection rates. We made great progress to address the billing system issue and remain confident in our outlook for the remainder of the year.”
Revenue of $90.4 million, growing approximately 8% year-over-year
* GAAP gross profit of $31.9 million, or GAAP gross margin of 35.3%; Non-GAAP gross profit of $32.8 million, or Non-GAAP gross margin of 36.3%
Get started
Create a free account to read the full story.